Wongpratate Mayuree, Bumrungthai Sureewan
Department of Faculty of Medicine, Mahasarakham University, Maha Sarakham, Thailand.
Department of Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.
Obstet Gynecol Sci. 2024 May;67(3):261-269. doi: 10.5468/ogs.23277. Epub 2024 Mar 25.
Cervical cancer continues to pose a challenge to the health of Thai women, as the second most common cancer after breast cancer. Since high-risk human papillomavirus (HPV) types are the main cause for cervical cancer, cervical cancer screening and HPV vaccination are necessary to reduce the incidence of this disease. At present, the World Health Organization hopes to reduce the incidence of cervical cancer to 4 or less cases per 100,000 women-years using 90%- 70%-90% intervention by 2030. The first intervention involves vaccinating 90% of women aged 15 years with the HPV vaccine. The second intervention involves screening 70% of women between the ages of 35 and 45 years using a high-performance screening test. The third intervention involves detecting cervical lesions in 90% of affected women to enable diagnosis and treatment. In this context, this study reviews trends in the incidence and mortality rates of cervical cancer in Thailand, in addition to providing an up-to-date overview of the causes and necessary risk factors for cervical cancer, as well as reporting on cervical screening and HPV vaccination rates and cervical cancer during the coronavirus disease 2019 (COVID-19) pandemic. This study may prove useful for the formulation of policy aimed at eliminating cervical cancer in Thailand, such as the implementation of a free HPV vaccine service and providing athome kits for cervical screening through clinics and pharmacies. In addition, this review also highlights the need for further research on the effects of the COVID-19 pandemic on cervical cancer screening rates in Thailand.
宫颈癌仍然对泰国女性的健康构成挑战,是仅次于乳腺癌的第二大常见癌症。由于高危型人乳头瘤病毒(HPV)是宫颈癌的主要病因,因此宫颈癌筛查和HPV疫苗接种对于降低该疾病的发病率至关重要。目前,世界卫生组织希望到2030年通过90%-70%-90%干预措施将宫颈癌发病率降低至每10万妇女年4例或更少。第一项干预措施是为90%的15岁女性接种HPV疫苗。第二项干预措施是使用高效筛查测试对70%的35至45岁女性进行筛查。第三项干预措施是在90%的受影响女性中检测宫颈病变,以便进行诊断和治疗。在此背景下,本研究回顾了泰国宫颈癌的发病率和死亡率趋势,此外还提供了宫颈癌病因和必要风险因素的最新概述,并报告了2019冠状病毒病(COVID-19)大流行期间的宫颈癌筛查和HPV疫苗接种率以及宫颈癌情况。本研究可能对制定旨在消除泰国宫颈癌的政策有用,例如实施免费HPV疫苗服务以及通过诊所和药店提供用于宫颈癌筛查的家用试剂盒。此外,本综述还强调了有必要进一步研究COVID-19大流行对泰国宫颈癌筛查率的影响。